Lifecore Biomedical Statistics
Share Statistics
Lifecore Biomedical has 37.03M shares outstanding. The number of shares has increased by 20.56% in one year.
| Shares Outstanding | 37.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 19.32% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.84M |
| Failed to Deliver (FTD) Shares | 562 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 2.35M, so 6.39% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 6.39% |
| Short % of Float | 7.2% |
| Short Ratio (days to cover) | 11.92 |
Valuation Ratios
The PE ratio is 14.26 and the forward PE ratio is -9.89.
| PE Ratio | 14.26 |
| Forward PE | -9.89 |
| PS Ratio | 1.34 |
| Forward PS | 1.7 |
| PB Ratio | 3.18 |
| P/FCF Ratio | -9.44 |
| PEG Ratio | n/a |
Enterprise Valuation
Lifecore Biomedical Inc. has an Enterprise Value (EV) of 331.52M.
| EV / Earnings | 27.6 |
| EV / Sales | 2.58 |
| EV / EBITDA | 9.31 |
| EV / EBIT | 35.53 |
| EV / FCF | -18.28 |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 2.42.
| Current Ratio | 2.08 |
| Quick Ratio | 1.06 |
| Debt / Equity | 2.42 |
| Total Debt / Capitalization | 70.75 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0.52 |
Financial Efficiency
Return on equity (ROE) is 0.22% and return on capital (ROIC) is 4.97%.
| Return on Equity (ROE) | 0.22% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 4.97% |
| Revenue Per Employee | 244.77K |
| Profits Per Employee | 22.93K |
| Employee Count | 524 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.16 |
Taxes
| Income Tax | 183.00K |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by -5.18% in the last 52 weeks. The beta is 0.94, so Lifecore Biomedical 's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -5.18% |
| 50-Day Moving Average | 6.98 |
| 200-Day Moving Average | 5.87 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 247.71K |
Income Statement
In the last 12 months, Lifecore Biomedical had revenue of 128.26M and earned 12.01M in profits. Earnings per share was 0.39.
| Revenue | 128.26M |
| Gross Profit | 41.85M |
| Operating Income | 9.33M |
| Net Income | 12.01M |
| EBITDA | 35.60M |
| EBIT | 9.33M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 8.46M in cash and 130.36M in debt, giving a net cash position of -121.90M.
| Cash & Cash Equivalents | 8.46M |
| Total Debt | 130.36M |
| Net Cash | -121.90M |
| Retained Earnings | -166.52M |
| Total Assets | 255.39M |
| Working Capital | 46.57M |
Cash Flow
In the last 12 months, operating cash flow was -217.00K and capital expenditures -17.92M, giving a free cash flow of -18.14M.
| Operating Cash Flow | -217.00K |
| Capital Expenditures | -17.92M |
| Free Cash Flow | -18.14M |
| FCF Per Share | -0.6 |
Margins
Gross margin is 32.63%, with operating and profit margins of 7.28% and 9.37%.
| Gross Margin | 32.63% |
| Operating Margin | 7.28% |
| Pretax Margin | 7.42% |
| Profit Margin | 9.37% |
| EBITDA Margin | 27.76% |
| EBIT Margin | 7.28% |
| FCF Margin | -14.14% |
Dividends & Yields
LFCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 6.08% |
| FCF Yield | -7.64% |
Analyst Forecast
The average price target for LFCR is $8, which is 24.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 24.8% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.18 |
| Piotroski F-Score | 6 |